Tazoral Risk Management Plan Resubmission May Affect Approval Timeline

Allergan will resubmit a revised risk management program for Tazoral as a result of the negative review by FDA’s advisory committees. The resubmission could extend the user fee date of the oral retinoid, Allergan says.